1018-00009 · Client 1018 · Strategy

irc-482-legal-analysis-memo.docx DOCUMENT M&A / Corporate

160 / 176 ← → ✕

PRIVILEGED & CONFIDENTIAL — ATTORNEY WORK PRODUCT

This memorandum is protected by the attorney-client privilege, the work product doctrine, and all other applicable privileges. It is prepared in anticipation of litigation and reflects the mental impressions, conclusions, opinions, and legal theories of attorneys at Calderwood & Harkness LLP. This memorandum and its contents shall not be disclosed to any person or entity outside the attorney-client relationship without the prior written consent of Calderwood & Harkness LLP and Penterra Pharmaceuticals Corp.

CALDERWOOD & HARKNESS LLP 1100 Connecticut Avenue, N.W., Suite 1400 Washington, D.C. 20036 Telephone: (202) 555-8200 Facsimile: (202) 555-8201

MEMORANDUM

TO: Leonard Cross, Responsible Partner, Tax Department Sylvia Hartwell, Billing Partner, Tax Department

FROM: Leila Nazari, Working Associate, Tax Department Garrett Simmons, Lead Associate, Tax Department

DATE: July 20, 2022

RE: Legal Analysis — IRC § 482 Arm's-Length Standard and Best Method Rule: Framework for Evaluating Penterra Pharmaceuticals Corp. Transfer Pricing Methodologies

MATTER NO.: 1018-00009

CLIENT: Penterra Pharmaceuticals Corp. (EIN: 22-3741856)

TAX YEARS AT ISSUE: 2017, 2018, 2019, 2020

IRS EXAM TEAM ID: LB&I-NE-TP-2022-00641

Right-click to update Table of Contents

I. Executive Summary

The purpose of this memorandum is to provide a comprehensive legal framework for evaluating the transfer pricing positions of Penterra Pharmaceuticals Corp. ("PPC" or the "Company") in connection with the examination initiated by the Internal Revenue Service Large Business & International Division ("LB&I"). On May 16, 2022, the IRS issued Letter 2205-A to PPC, formally opening an examination of the Company's federal income tax returns for tax years 2017 through 2020. The central focus of the examination is the intercompany transfer pricing methodology used between PPC's U.S. operations and its Irish subsidiary, Penterra Biopharma International DAC ("PBI"), through which PPC conducts a substantial portion of its non-Americas pharmaceutical commercialization activities.

Two principal intercompany arrangements are under scrutiny. First, the cost-sharing arrangement ("CSA"), effective July 1, 2012, under which PPC and PBI share the costs and risks associated with the development of pharmaceutical intangibles, and which included a platform contribution transaction ("PCT") payment of $312 million made by PBI to PPC as a buy-in to PPC's pre-existing intangible property portfolio. Second, the legacy intellectual property royalty arrangement, under which PBI licenses certain pre-2012 vintage pharmaceutical compounds from PPC at a royalty rate of 4.5% of net sales for non-Americas territories.

This memorandum analyzes the following legal and regulatory authorities as they apply to PPC's arrangements:

(a) The arm's-length standard under IRC § 482 and Treas. Reg. § 1.482-1(b), which governs the determination of taxable income among commonly controlled entities;

(b) The best method rule under Treas. Reg. § 1.482-1(c), which requires that the transfer pricing method producing the most reliable measure of an arm's-length result be applied;

(c) The specific methods applicable to intangible property transfers under Treas. Reg. § 1.482-4, including the comparable uncontrolled transaction ("CUT") method, the comparable profits method ("CPM"), the profit split method, and the income method;

(d) The cost-sharing arrangement requirements under Treas. Reg. § 1.482-7, including the provisions governing platform contribution transactions and the determination of reasonably anticipated benefits; and

(e) Key judicial precedent, including Altera Corp. v. Commissioner, 941 F.3d 1200 (9th Cir. 2019); Harborview Corporation, Inc. v. Commissioner, 147 T.C. 35 (2016), remanded, 900 F.3d 610 (8th Cir. 2018); and Hollowell & Co. v. Commissioner, 148 T.C. 108 (2017).

Based on the analysis set forth herein, we conclude that PPC's CSA cost-sharing ratios (ranging from 38.2% to 42.7% for tax years 2017 through 2020), the PCT valuation of $312 million, and the legacy IP royalty rate of 4.5% are defensible under the arm's-length standard and the best method analysis. The CUT method analysis yields an interquartile range of 3.1% to 6.8% (median of 4.4%) for comparable pharmaceutical license agreements, and PPC's 4.5% rate falls squarely within that range. The income method/Discounted cash flow ("DCF") analysis supports a PCT valuation range of $278 million to $361 million, within which PPC's $312 million payment is comfortably situated. The cost-sharing ratios, premised on reasonably anticipated benefits ("RAB") measured by prospective revenue projections, are consistent with the requirements of Treas. Reg. § 1.482-7(e).

Notwithstanding the defensibility of PPC's positions, this memorandum identifies specific areas of potential IRS challenge, including the selection criteria for CUT comparables, the discount rate employed in the PCT DCF valuation, the reasonableness of PPC's ex ante RAB projections, and PBI's economic substance and control over development, enhancement, maintenance, protection, and exploitation ("DEMPE") functions. We provide recommendations for bolstering PPC's positions in anticipation of these challenges, including directions for the economic analyses to be performed by Whitmore Valuation Group LLC under our Kovel engagement.

II. Scope and Background

A. Engagement Context

Calderwood & Harkness LLP was engaged by Penterra Pharmaceuticals Corp. on June 2, 2022, as outside tax counsel to represent and defend PPC in connection with the IRS examination of its federal income tax returns for tax years 2017, 2018, 2019, and 2020. The engagement letter, executed by PPC's Senior Vice President and General Tax Counsel, Rebecca Thornton, provides for Calderwood & Harkness to serve as lead counsel in all matters relating to the IRS examination, including the preparation and filing of responses to Information Document Requests ("IDRs"), the development of transfer pricing defense strategy, the engagement and supervision of experts, and, if necessary, the representation of PPC in administrative appeals, competent authority proceedings, or Tax Court litigation.

The IRS examination was opened on May 16, 2022, by Supervisory Revenue Agent Gerald Meskill, assigned to the LB&I Northeast Transfer Pricing Practice. The lead Revenue Agent on the examination is Patricia Dunleavy, a seasoned examiner with significant experience in pharmaceutical transfer pricing matters. Notably, the IRS has assigned two additional subject-matter specialists to the examination: Dr. Alan Washburne, an economist with the IRS Transfer Pricing Practice who is expected to lead the Service's economic analysis of PPC's intercompany pricing, and Attorney-Advisor Franklin Rosario of the IRS Office of Chief Counsel, International Division, who will provide legal guidance to the examination team. The assignment of both an economist and an attorney-advisor at this early stage of the examination signals the IRS's intent to devote substantial resources to challenging PPC's transfer pricing positions.

PPC was not enrolled in the IRS Compliance Assurance Process ("CAP") for any of the tax years at issue. As a result, PPC's transfer pricing positions were not pre-reviewed or pre-approved by the IRS prior to the filing of its returns for 2017 through 2020. This distinguishes PPC from several of its pharmaceutical-industry peers that have participated in CAP and resolved transfer pricing issues prospectively.

On June 20, 2022, Calderwood & Harkness executed a Kovel engagement letter with Whitmore Valuation Group LLC, designating Dr. Helena Vasquez, Managing Director and Lead Economist, as the firm's lead economic expert for purposes of the examination. The Kovel engagement is structured to ensure that all communications between Whitmore, Calderwood & Harkness, and PPC are protected under the attorney-client privilege and the work product doctrine, consistent with the framework established in United States v. Kovel, 296 F.2d 918 (2d Cir. 1961). Dr. Vasquez brings more than twenty years of experience in pharmaceutical transfer pricing and has served as a testifying expert in multiple Tax Court proceedings involving § 482 disputes.

B. PPC's Global Corporate Structure

An understanding of PPC's corporate structure is essential to the transfer pricing analysis, as the structure defines the controlled relationships at issue and the allocation of functions, assets, and risks among the entities.

Penterra Pharmaceuticals Corp. ("PPC") is a Delaware corporation, publicly traded on the Nasdaq Global Select Market under the ticker symbol PPCA, with its principal executive offices located at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. PPC is a specialty pharmaceutical and biotechnology company focused on three primary therapeutic areas: oncology, immunology, and rare-disease therapeutics. For fiscal year 2020, PPC reported consolidated revenue of approximately $6.82 billion, pre-tax income of approximately $1.47 billion, and employed approximately 14,500 individuals worldwide. PPC maintains its primary research and development operations in Princeton Junction and at satellite laboratories in Cambridge, Massachusetts, and San Diego, California. PPC's U.S. commercial operations are responsible for the marketing and distribution of PPC's pharmaceutical products throughout the Americas region, defined under the CSA as North America, Central America, South America, and the Caribbean.

Penterra Holdings Luxembourg S.à r.l. ("PHL") is a société à responsabilité limitée organized under the laws of the Grand Duchy of Luxembourg (Registre de Commerce et des Sociétés No. B 168452), with its registered office at 14, rue Aldringen, L-1118 Luxembourg. PHL is 100% owned by PPC. PHL is treated as a disregarded entity for U.S. federal income tax purposes under Treas. Reg. § 301.7701-3, and accordingly, all transactions between PHL and PBI, or between PHL and PPC, are treated for U.S. tax purposes as transactions directly between PPC and PBI. PHL's function in the corporate structure is primarily as an intermediate holding entity, and it does not conduct any substantive operational activities.

Penterra Biopharma International DAC ("PBI") is a Designated Activity Company organized under Irish law, with its registered office at 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland (Irish Tax Reference: 3218764T). PBI is 100% owned by PHL (and thus, through the disregarded-entity treatment, is treated for U.S. tax purposes as owned directly by PPC). PBI functions as the intellectual property holding company and commercial principal for PPC's pharmaceutical products outside the Americas. PBI holds the rights to develop and exploit PPC's pharmaceutical IP portfolio for non-Americas territories pursuant to the CSA, and licenses certain pre-2012 legacy compounds from PPC under the legacy IP royalty arrangement. For fiscal year 2020, PBI reported revenue of approximately €2.14 billion and pre-tax income of approximately €1.06 billion. PBI has grown substantially since its incorporation in March 2012, from 52 employees at inception to approximately 185 employees as of December 31, 2020. PBI's Managing Director is Aidan Naughton, who operates from PBI's Dublin headquarters and oversees all non-Americas commercial operations. PBI is subject to the standard Irish corporate income tax rate of 12.5% on trading income. Beginning in fiscal year 2016, PBI has also availed itself of Ireland's Knowledge Development box ("KDB") regime, which provides an effective tax rate of 6.25% on qualifying income derived from qualifying assets, including patented pharmaceutical compounds.

Penterra Manufacturing Ireland Ltd. ("PMI") is an Irish private limited company (Companies Registration Office No. 512347), with its registered office at Unit 7, Ringaskiddy Industrial Estate, Co. Cork T12 PX29, Ireland. PMI is 100% owned by PBI and operates as a contract manufacturer of oncology and immunology biologic products for non-Americas markets. PMI manufactures under a cost-plus arrangement with PBI, earning a markup of cost plus 8%, which is consistent with the contract manufacturing benchmarking analysis included in PPC's contemporaneous transfer pricing documentation. PMI employs approximately 620 individuals at its Cork manufacturing facility, which includes a state-of-the-art biologics production suite and quality assurance laboratory.

C. The Intercompany Arrangements at Issue

The IRS examination focuses on two intercompany arrangements between PPC and PBI. Each arrangement involves the transfer, license, or shared development of intangible property, and each is subject to the arm's-length standard under IRC § 482 and the associated Treasury Regulations.

1. Cost-Sharing Arrangement (CSA)

The CSA was executed effective July 1, 2012, between PPC and PBI (through PHL, disregarded). Under the CSA, PBI acquired the right to develop and exploit PPC's pharmaceutical IP portfolio outside the Americas—defined to encompass all territories other than North America, Central America, South America, and the Caribbean—in exchange for: (a) a lump-sum PCT payment of $312 million, representing the fair value of PPC's pre-existing intangible property contributed to the CSA (primarily clinical-stage and approved oncology compounds); and (b) ongoing cost-sharing payments proportional to each participant's reasonably anticipated benefits from the intangible development activities ("IDA") conducted under the CSA.

PCT Payment. The $312 million lump-sum PCT payment was made by PBI to PPC on July 1, 2012. The payment was calculated using the income method described in Treas. Reg. § 1.482-7(g)(4), which involves discounting the anticipated future income attributable to the pre-existing intangible property at an appropriate discount rate. PPC employed a weighted average cost of capital ("WACC") of 9.8% in the DCF analysis, reflecting pharmaceutical-industry risk premiums, the early-stage development uncertainty associated with clinical-stage compounds, and the regulatory risks inherent in obtaining marketing approvals across multiple global jurisdictions. The $312 million figure represents a single point estimate within what Whitmore Valuation Group has confirmed is an arm's-length range of $278 million to $361 million.

Cost-Sharing Ratios (2017–2020). Under the CSA, each participant's share of the annual qualified research and development costs is determined based on its RAB share, which is recalculated annually based on prospective revenue projections for the Americas and non-Americas territories. For the tax years at issue, PBI's RAB share and corresponding cost-sharing payments were as follows:

The gradual increase in PBI's RAB share from 38.2% to 42.7% over the four-year period reflects PBI's expanding non-Americas market penetration, which in turn reflects PBI's successful commercialization efforts in European, Asia-Pacific, and other international markets. The increase is consistent with actual revenue trends, as PBI's non-Americas net sales grew proportionately relative to PPC's Americas net sales over this period.

2. Legacy IP Royalty Arrangement

Separate from the CSA, PBI licensed certain pre-2012 vintage legacy compounds from PPC pursuant to a formal license agreement executed contemporaneously with the CSA. The legacy IP royalty arrangement covers pharmaceutical compounds that were fully developed and commercialized prior to the effective date of the CSA and that were not contributed to the CSA's intangible development program. Under the license, PBI pays PPC a royalty of 4.5% of net sales for non-Americas territories. The royalty rate was determined on the basis of a CUT analysis identifying comparable pharmaceutical license agreements between unrelated parties.

Legacy compound non-Americas net sales and royalty payments for the tax years at issue were as follows:

The declining trajectory of legacy compound net sales is consistent with the natural lifecycle of mature pharmaceutical products, as newer compounds developed under the CSA increasingly capture market share and as certain legacy compounds face generic competition in key international markets.

3. Key Products

PPC's product portfolio includes several significant pharmaceutical products that generate substantial global revenues. The three most commercially significant products are:

Veritaxol — PPC's oncology blockbuster. Veritaxol is a monoclonal antibody indicated for the treatment of advanced non-small cell lung cancer and metastatic colorectal cancer. For fiscal year 2020, Veritaxol generated global net sales of approximately $3.12 billion, of which approximately $1.34 billion was attributable to non-Americas territories. Veritaxol is PPC's single largest revenue-generating product and is at the center of the CSA's commercial significance.

Imvara — PPC's immunology franchise product. Imvara is a biologic therapy approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and moderate-to-severe plaque psoriasis. For fiscal year 2020, Imvara generated global net sales of approximately $1.87 billion, with approximately $0.79 billion attributable to non-Americas territories.

Cerulon — PPC's rare-disease product. Cerulon is an enzyme replacement therapy for the treatment of a rare lysosomal storage disorder. For fiscal year 2020, Cerulon generated global net sales of approximately $0.62 billion, with approximately $0.28 billion attributable to non-Americas territories.

4. Contemporaneous Transfer Pricing Documentation

PPC's contemporaneous transfer pricing documentation for all four tax years at issue (2017, 2018, 2019, and 2020) was prepared by Crestfield & Associates LLP, under the supervision of Susan Lam, Transfer Pricing Partner. The documentation was prepared to meet the standards set forth in IRC § 6662(e) and the associated regulations for penalty protection purposes. The documentation includes, for each tax year, a comprehensive functional analysis, a description of the intercompany transactions, an evaluation of the available transfer pricing methods under the best method rule, a detailed benchmarking analysis identifying comparable uncontrolled transactions (for the royalty) and comparable companies (for CPM/TNMM profitability testing), and a conclusion as to the arm's-length nature of PPC's intercompany pricing. The existence and quality of this contemporaneous documentation is a significant factor in PPC's defense against potential IRS adjustments and penalty exposure.

D. Purpose of This Memorandum

This memorandum is intended to accomplish the following objectives:

(1) Establish the legal framework governing the arm's-length standard under IRC § 482 and its implementing regulations, with particular emphasis on the provisions applicable to controlled transfers of intangible property and cost-sharing arrangements;

(2) Apply the best method rule, as articulated in Treas. Reg. § 1.482-1(c), to PPC's chosen transfer pricing methods—specifically, the CUT method for the legacy IP royalty, the income method/DCF for the PCT valuation, and the RAB-based method for the CSA cost-sharing ratios—and evaluate whether these methods satisfy the requirements for producing the most reliable arm's-length result;

(3) Survey the controlling judicial precedent, including the Ninth Circuit's decision in Altera, the Tax Court and Eighth Circuit decisions in Harborview Corporation, and the Tax Court's decision in Penmark Holdings, and assess their implications for PPC's positions;

(4) Identify the potential arguments that the IRS examination team—including Dr. Washburne and Attorney-Advisor Rosario—may raise in challenging PPC's transfer pricing positions, and assess the strength and vulnerability of those arguments;

(5) Provide a foundation for the independent economic analyses to be performed by Whitmore Valuation Group LLC (Dr. Vasquez) under the Kovel arrangement, and for the development of PPC's IDR response strategy; and

(6) Serve as a predicate for the series of companion memoranda that will address specific aspects of PPC's transfer pricing defense in greater detail, as outlined in Appendix C to this memorandum.

III. Statutory Framework: IRC § 482

A. Text and Purpose of IRC § 482

Section 482 of the Internal Revenue Code provides the statutory authority for the Secretary of the Treasury, acting through the Internal Revenue Service, to allocate gross income, deductions, credits, or allowances among two or more organizations, trades, or businesses that are owned or controlled, directly or indirectly, by the same interests. The statute provides, in relevant part:

"In any case of two or more organizations, trades, or businesses (whether or not incorporated, whether or not organized in the United States, and whether or not affiliated) owned or controlled directly or indirectly by the same interests, the Secretary may distribute, apportion, or allocate gross income, deductions, credits, or allowances between or among such organizations, trades, or businesses, if he determines that such distribution, apportionment, or allocation is necessary in order to prevent evasion of taxes or clearly to reflect the income of any of such organizations, trades, or businesses."

The language of § 482 is intentionally broad in scope, and the requirement of common ownership or control is satisfied by a wide range of relationships. In PPC's case, the common control requirement is unambiguously met: PPC directly owns 100% of PHL, which in turn directly owns 100% of PBI. Because PHL is treated as a disregarded entity for U.S. federal income tax purposes under the check-the-box regulations of Treas. Reg. § 301.7701-3, PBI is treated for all § 482 purposes as directly controlled by PPC. There is no dispute between PPC and the IRS as to the existence of common control, and the threshold jurisdictional requirement of § 482 is clearly satisfied.

The purpose of § 482 has been articulated by courts and the Treasury Department in two complementary formulations. First, § 482 serves to place a controlled taxpayer on a tax parity with an uncontrolled taxpayer by determining the true taxable income from the property and business of each entity in the controlled group. See Treas. Reg. § 1.482-1(a)(1). The regulation states that the purpose is to "ensure that taxpayers clearly reflect income attributable to controlled transactions, and to prevent the avoidance of taxes with respect to such transactions." Second, and relatedly, § 482 serves to prevent the artificial shifting of income between commonly controlled entities that might otherwise exploit differences in tax rates across jurisdictions. This purpose is particularly relevant in PPC's case, where the U.S. corporate tax rate (35% for tax year 2017 and 21% for tax years 2018–2020 following the Tax Cuts and Jobs Act) significantly exceeds the Irish corporate tax rate of 12.5% on trading income (and the Knowledge Development box rate of 6.25% on qualifying income), creating a natural incentive for income-shifting from the United States to Ireland.

It is critical to note, however, that § 482 is not a penal statute. As the Tax Court has repeatedly emphasized, the allocation authority under § 482 is corrective in nature, designed to ensure that controlled transactions produce results consistent with the arm's-length standard rather than to punish taxpayers for engaging in intercompany transactions. See, e.g., Commissioner v. First Security Bank of Utah, 405 U.S. 394, 400 (1972); B. Forman Co. v. Commissioner, 453 F.2d 1144, 1151 (2d Cir. 1972). The IRS's authority under § 482 is not unlimited; it is constrained by the requirement that any allocation must reflect an arm's-length result, and the IRS cannot reallocate income in a manner that exceeds what would have resulted from dealings between uncontrolled parties acting at arm's length.

A significant contextual consideration for PPC's examination is the change in the U.S. corporate tax rate brought about by the TCJA, which reduced the rate from 35% to 21% effective January 1, 2018. For tax year 2017 (the only pre-TCJA year at issue), the 35% U.S. rate created a 22.5 percentage-point differential relative to Ireland's 12.5% rate, while for tax years 2018–2020, the post-TCJA differential narrowed to 8.5 percentage points (or 14.75 percentage points relative to the 6.25% KDB rate). The larger pre-TCJA differential increases the IRS's incentive to challenge income-shifting arrangements for 2017, as the tax effect of any § 482 adjustment is correspondingly larger for that year.

B. The Arm's-Length Standard — Treas. Reg. § 1.482-1(b)

The arm's-length standard is the foundational principle governing all allocations and adjustments under IRC § 482. Treasury Regulation § 1.482-1(b)(1) provides:

"In determining the true taxable income of a controlled taxpayer, the standard to be applied in every case is that of a taxpayer dealing at arm's length with an uncontrolled taxpayer. A controlled transaction meets the arm's length standard if the results of the transaction are consistent with the results that would have been realized if uncontrolled taxpayers had engaged in the same transaction under the same circumstances (arm's length result)."

The arm's-length standard thus requires a comparison between the terms and results of controlled transactions and those that would have been achieved in comparable transactions between independent parties. The standard does not require that controlled parties actually mirror specific transactions between unrelated parties; rather, it requires that the economic outcomes of controlled transactions be consistent with the range of outcomes that arm's-length parties would have achieved under comparable circumstances.

The regulation further provides that the arm's-length standard is generally applied on a transaction-by-transaction basis. See Treas. Reg. § 1.482-1(b)(2)(i). However, the regulations recognize that in certain cases, two or more transactions may be so interrelated that they should be aggregated and evaluated together. This aggregation principle may be relevant to PPC's arrangements, where the CSA and the legacy IP royalty arrangement collectively define the economic relationship between PPC and PBI with respect to PPC's pharmaceutical IP portfolio. Nevertheless, the two arrangements involve distinct categories of intangible property (post-2012 CSA-developed IP versus pre-2012 legacy IP) and are governed by separate contractual instruments, supporting their treatment as separate transactions for arm's-length analysis purposes.

Central to the arm's-length standard is the concept of comparability. To determine whether a controlled transaction produces an arm's-length result, it is necessary to identify comparable uncontrolled transactions and to compare the controlled and uncontrolled transactions on the basis of their economically relevant characteristics. The comparability analysis is discussed in detail in Section III.C below.

The regulations also establish the concept of the arm's-length range, which recognizes that the application of a transfer pricing method typically does not produce a single arm's-length price or result but rather a range of prices or results, any of which could reasonably have been achieved by uncontrolled parties. Where a controlled transaction falls within the arm's-length range, no adjustment is warranted. Where it falls outside the range, the IRS may adjust the controlled taxpayer's income to bring it within the range. The arm's-length range is discussed in detail in Section III.D below.

C. Comparability Factors — Treas. Reg. § 1.482-1(d)

The reliability of any transfer pricing analysis depends fundamentally on the quality of the comparability analysis. Treasury Regulation § 1.482-1(d) identifies a non-exhaustive set of factors that must be considered in evaluating the comparability of controlled and uncontrolled transactions. These factors are applicable across all transfer pricing methods and are critical to assessing the reliability of PPC's selected methods.

1. Functions Performed

The functional analysis is the starting point of any transfer pricing comparability assessment. Treas. Reg. § 1.482-1(d)(3)(i) requires consideration of the functions performed by each party to the controlled transaction, the assets employed, and the risks assumed. The functional analysis establishes the economic profile of each party and determines the appropriate characterization of the transaction for purposes of method selection and comparability.

In PPC's case, the functional analysis is of critical importance because the IRS may argue that the key DEMPE functions—development, enhancement, maintenance, protection, and exploitation—with respect to PPC's pharmaceutical IP portfolio were performed primarily by PPC's U.S.-based personnel, notwithstanding PBI's formal role as IP-holding company and non-Americas commercial principal. PBI's functional profile must therefore be carefully documented. As discussed in Section VII below, PBI employs 185 individuals (as of December 31, 2020), conducts independent commercial decision-making through its Dublin-based management team led by Managing Director Aidan Naughton, exercises independent pricing authority across 68 country markets, has conducted 42 board meetings during 2017–2020 (all held in Dublin), has incurred cumulative regulatory expenditures of €47.2 million, operates from approximately 18,000 square feet of office space in Dublin, and maintains independent banking relationships with Glenmore Bank Ireland plc. These facts are essential to establishing PBI's economic substance and its right to retain income commensurate with the functions it performs, the assets it employs, and the risks it assumes.

2. Contractual Terms

Treas. Reg. § 1.482-1(d)(3)(ii) provides that arm's-length parties typically formalize their dealings in contracts that reflect the economic substance of their arrangement. The regulations recognize that contract terms—including provisions regarding payment, duration, termination, volume, and scope of rights—can materially affect the pricing of a transaction and must be considered in the comparability analysis.

PPC has both a formal CSA agreement (executed July 1, 2012) and a formal legacy IP license agreement (executed contemporaneously). Both agreements were prepared with the assistance of outside counsel and reflect the commercially negotiated terms between PPC and PBI, including provisions addressing territorial scope, exclusivity, cost allocation, payment terms, dispute resolution, and termination. The existence of comprehensive written agreements is a positive factor in PPC's defense, as it demonstrates that the intercompany arrangements were structured with the formality and deliberateness characteristic of arm's-length dealings.

The regulations further provide, however, that the contractual terms of a controlled transaction must be consistent with the economic substance of the parties' actual conduct. See Treas. Reg. § 1.482-1(d)(3)(ii)(B). If the actual conduct of the parties is inconsistent with the contractual terms, the IRS may disregard the contract and recharacterize the transaction based on the economic substance of the parties' actual conduct. This principle is discussed further in connection with the "actual conduct" principle in Section III.C.5 below.

3. Risks Assumed

Treas. Reg. § 1.482-1(d)(3)(iii) requires consideration of the risks assumed by each party to the controlled transaction. Risk allocation is a critical factor in the comparability analysis because the assumption of economically significant risks is a key driver of profit potential. A party that bears greater risk is generally entitled to greater compensation.

In PPC's case, PBI bears significant risks in connection with its role as non-Americas commercial principal, including: (a) market risk associated with the commercialization of PPC's pharmaceutical products across diverse and heterogeneous international markets; (b) regulatory risk associated with obtaining and maintaining marketing approvals from regulatory authorities in 68 country markets; (c) pricing risk, as PBI independently sets prices and negotiates with payors, governments, and distributors in each country; (d) credit risk associated with sales to distributors and healthcare institutions in international markets; (e) foreign currency risk, as PBI's revenue is denominated in multiple currencies while its cost-sharing payments to PPC are denominated in U.S. dollars; and (f) development risk under the CSA, as PBI shares in the costs and outcomes of PPC's intangible development activities without any guarantee that such activities will produce commercially successful products.

The IRS may argue that PBI's risk assumption is nominal or that the risks are effectively managed and controlled by PPC's U.S.-based operations. PPC must be prepared to demonstrate, through documentary evidence and witness testimony, that PBI exercises genuine independent decision-making authority with respect to the risks it bears, consistent with the risk analysis framework established in the OECD Transfer Pricing Guidelines (2017), Chapter I.

4. Economic Conditions

Treas. Reg. § 1.482-1(d)(3)(iv) requires consideration of the economic conditions prevailing in the markets in which the controlled and uncontrolled transactions take place. Relevant economic conditions include market size, level of competition, availability of substitute goods or services, purchasing power, regulatory environment, and geographic location.

The pharmaceutical industry presents unique economic conditions that must be reflected in the comparability analysis. Pharmaceutical products are characterized by long development timelines (often 10–15 years from discovery to market), extensive regulatory requirements, significant development costs and failure rates, patent protection and exclusivity periods, geographic variability in pricing and reimbursement regimes, and the periodic impact of generic and biosimilar competition upon patent expiration. These industry-specific characteristics affect both the selection of comparables and the economic assumptions underlying PPC's transfer pricing methods.

5. Property or Services Transferred

Treas. Reg. § 1.482-1(d)(3)(v) requires consideration of the nature of the property or services transferred in the controlled transaction. In PPC's case, the property at issue consists of pharmaceutical intangible property—specifically, patents, trade secrets, know-how, clinical data, regulatory filings and approvals, and associated rights relating to PPC's oncology, immunology, and rare-disease therapeutic compounds. Pharmaceutical intangibles are highly specialized and differentiated, and their value is driven by factors such as the stage of clinical development, the breadth and quality of the patent portfolio, the competitive landscape, the size of the addressable patient population, and the anticipated duration of market exclusivity.

The specialized and differentiated nature of pharmaceutical intangibles is relevant to the best method analysis because it affects the availability and reliability of comparables. As discussed in Section IV below, truly comparable uncontrolled transactions involving pharmaceutical intangibles of similar nature, scope, and stage of development may be limited, which in turn affects the reliability of the CUT method and may support the use of alternative methods such as the income method or the profit split method.

6. Actual Conduct Principle

The regulations emphasize that the economic substance of a transaction, not merely its legal form, controls the transfer pricing analysis. Treas. Reg. § 1.482-1(d)(3)(ii)(B) provides that where the actual conduct of the parties is inconsistent with the written terms of their agreement, the IRS may disregard the contractual provisions and determine the true terms of the transaction based on the parties' actual conduct. This "actual conduct" principle is a powerful tool in the IRS's arsenal, as it enables the Service to look beyond formal contractual arrangements and assess whether the economic reality of the controlled relationship matches the allocation of income reflected in the taxpayer's transfer pricing.

For PPC, the actual conduct principle underscores the importance of ensuring that PBI's real-world activities, decision-making authority, and risk management are consistent with its contractual role as IP-holding company and non-Americas commercial principal. Any disconnect between PBI's formal responsibilities under the CSA and license agreement, on the one hand, and its actual day-to-day activities and decision-making processes, on the other, could provide the IRS with a basis for recharacterizing the intercompany arrangements and reallocating income to PPC.

D. Arm's-Length Range — Treas. Reg. § 1.482-1(e)

The arm's-length range is a critical concept in the application of any transfer pricing method. Treasury Regulation § 1.482-1(e)(2) provides that where the application of a transfer pricing method produces a range of results from comparable uncontrolled transactions, the arm's-length range is established by the interquartile range—that is, the range of results from the 25th percentile to the 75th percentile—of the results.

If the controlled taxpayer's result falls within the interquartile range, the result is treated as arm's-length and no adjustment is warranted. If the controlled taxpayer's result falls outside the interquartile range, the IRS may adjust the taxpayer's income to a point within the range. Treas. Reg. § 1.482-1(e)(3) provides that, in such cases, the adjusted result is typically the median of the comparable results, though other points within the range may be appropriate depending on the facts and circumstances.

The interquartile range methodology applies to all transfer pricing methods, though the specific results and their distribution will vary depending on the method applied and the quality of the available comparables. For PPC, the application of the arm's-length range concept is relevant in two principal respects:

First, the CUT analysis for the legacy IP royalty rate yields an interquartile range of 3.1% to 6.8%, with a median of 4.4%. PPC's 4.5% rate falls within this range and is essentially at the median, providing strong support for PPC's position.

Second, the CPM/TNMM analysis of PBI's overall profitability, which serves as a cross-check on the reasonableness of PBI's income retention, will produce an interquartile range of operating margins or Berry ratios derived from comparable companies. PBI's actual profitability must fall within this range to be defensible.

The arm's-length range concept is also relevant to the PCT valuation. Whitmore Valuation Group's income method/DCF analysis produces a range of $278 million to $361 million, representing the sensitivity of the DCF output to reasonable variations in key assumptions (principally the discount rate and revenue projections). PPC's $312 million PCT payment falls within this range.

IV. The Best Method Rule — Treas. Reg. § 1.482-1(c)

A. Overview

The best method rule is the cornerstone of method selection under IRC § 482 and its implementing regulations. Treasury Regulation § 1.482-1(c) provides:

"The arm's length result of a controlled transaction must be determined under the method that, under the facts and circumstances, provides the most reliable measure of an arm's length result."

This deceptively simple formulation embodies a principle of considerable practical significance: there is no hierarchy of methods, and no single method is preferred as a matter of principle over any other. Rather, the best method for a particular controlled transaction depends on the specific facts and circumstances of that transaction, including the nature of the property or services at issue, the availability and quality of data, and the degree of comparability between the controlled and uncontrolled transactions being compared.

The absence of a formal hierarchy means that the taxpayer has flexibility in selecting its transfer pricing method, but it also means that the IRS has the authority to challenge the taxpayer's method selection if the Service can demonstrate that an alternative method would produce a more reliable arm's-length result. Conversely, if the taxpayer can demonstrate that its chosen method satisfies the best method rule, the IRS cannot simply substitute a different method merely because the alternative method produces a different (and higher) allocation of income to the United States.

Notwithstanding the absence of a formal hierarchy, the regulations observe that "if two or more applications of a single method provide inconsistent results, the relative reliability of each application must be determined in light of the quality of the data and the assumptions used in each application." Treas. Reg. § 1.482-1(c)(1). Moreover, the regulations note that where a CUT of high reliability is available—that is, where the comparable uncontrolled transaction is sufficiently similar in all material respects to the controlled transaction—the CUT method will typically be the best method because it provides the most direct measure of an arm's-length price. This observation is particularly relevant to PPC's legacy IP royalty analysis, where the question of whether PPC's CUT comparables are of sufficiently high reliability is likely to be a central point of contention with the IRS.

B. Factors in Determining the Best Method

The regulations identify three principal factors for determining which method provides the most reliable measure of an arm's-length result under the facts and circumstances:

1. Degree of Comparability

The first and most important factor is the degree of comparability between the controlled transaction and the uncontrolled transactions, comparables, or other data used in applying the method. The method that relies on the closest factual comparables—considering all of the comparability factors described in Treas. Reg. § 1.482-1(d) and discussed in Section III.C above—is generally the most reliable. See Treas. Reg. § 1.482-1(c)(2)(i).

The degree of comparability is affected by the number and magnitude of adjustments necessary to account for differences between the controlled and uncontrolled transactions. A method that requires fewer and smaller adjustments is, all else being equal, more reliable than a method that requires numerous or large adjustments, because each adjustment introduces the possibility of error and reduces the confidence that can be placed in the ultimate result.

For PPC's legacy IP royalty, the CUT method relies on 14 comparable pharmaceutical license agreements identified by Whitmore Valuation Group. The degree of comparability of these agreements to PPC's legacy IP license turns on the similarity of the intangibles (therapeutic area, stage of development, competitive position), the terms of the license (exclusivity, duration, territory), and the functions, assets, and risks of the licensor and licensee. If these agreements are sufficiently comparable—requiring only modest adjustments for identifiable differences—the CUT method will satisfy the best method rule. If, however, the IRS can identify material differences that cannot be reliably adjusted for, the CUT method's reliability may be undermined.

2. Quality of Data and Assumptions

The second factor is the quality of the data and assumptions used in applying the method. See Treas. Reg. § 1.482-1(c)(2)(ii). Methods that require fewer and more reliable assumptions produce more reliable results. For example, the CUT method, when highly comparable uncontrolled transactions are available, requires relatively few assumptions beyond the comparability adjustments themselves. In contrast, the income method for PCT valuation requires assumptions about future revenue growth rates, product life cycles, discount rates, tax rates, and terminal values, each of which introduces the possibility of error and subjective judgment.

The quality of data is also a function of the source and reliability of the information used. Publicly available data from arm's-length transactions between independent parties is generally considered more reliable than internal or estimated data. Similarly, contemporaneous data—data available at the time the controlled transaction was entered into—is generally more reliable than hindsight data when evaluating the reasonableness of the taxpayer's transfer pricing at the time it was established.

3. Sensitivity of Results to Deficiencies in Data and Assumptions

The third factor is the sensitivity of the method's results to deficiencies in the data or assumptions used. See Treas. Reg. § 1.482-1(c)(2)(iii). Some methods are inherently more sensitive than others to data imperfections. For example, the income method for PCT valuation is highly sensitive to the discount rate and revenue projection assumptions: small changes in the WACC or in the assumed growth rate of future revenues can produce dramatically different present values. As discussed in Section IV.D.3 below, the 260-basis-point difference between PPC's WACC of 9.8% and the IRS's potential WACC of 7.2% can produce a PCT valuation difference of hundreds of millions of dollars. Methods that are less sensitive to data imperfections are, all else being equal, more reliable.

Conversely, the CUT method, when applied to closely comparable transactions, is relatively insensitive to small data imperfections because it relies directly on observed arm's-length prices rather than on modeled or projected financial data. This relative insensitivity is one of the reasons the regulations suggest that a CUT of high reliability will typically be the best method.

C. Available Methods for Intangible Property — Treas. Reg. § 1.482-4

Treasury Regulation § 1.482-4 prescribes the specific methods available for determining the arm's-length charge for controlled transfers of intangible property. The regulations provide four specified methods and one catch-all provision for unspecified methods:

1. Comparable Uncontrolled Transaction (CUT) Method

The CUT method evaluates whether the amount charged in a controlled transfer of intangible property is arm's-length by reference to the amount charged in comparable uncontrolled transactions involving the transfer of the same or comparable intangible property under comparable circumstances. See Treas. Reg. § 1.482-4(c).

The CUT method is the most direct method for determining an arm's-length royalty rate because it compares the controlled transaction to actual arm's-length transactions between unrelated parties. When highly comparable CUTs are available, this method provides the most reliable measure of an arm's-length result and will typically satisfy the best method rule.

The application of the CUT method requires a detailed comparability analysis, focusing on factors including: (i) the similarity of the intangible property transferred (including its type, stage of development, expected profitability, and exclusivity); (ii) the terms of the license or transfer (including royalty base, payment schedule, and duration); (iii) the territorial scope of the rights transferred; (iv) the exclusivity of the rights; and (v) the functional profiles of the parties. See Treas. Reg. § 1.482-4(c)(2).

The CUT method is the method selected by PPC for its legacy IP royalty arrangement. As discussed in Section VII.A below, PPC's contemporaneous documentation and Whitmore's independent analysis identify 14 comparable pharmaceutical license agreements that support an interquartile range of 3.1% to 6.8% and a median of 4.4%, within which PPC's 4.5% rate falls.

2. Comparable Profits Method (CPM)

The comparable profits method evaluates whether the amount charged in a controlled transaction is arm's-length based on objective measures of profitability (profit level indicators or "PLIs") derived from uncontrolled taxpayers that engage in comparable activities under comparable circumstances. See Treas. Reg. § 1.482-5. The CPM corresponds to the Transactional Net Margin Method ("TNMM") used under the OECD Transfer Pricing Guidelines.

The CPM is a one-sided method that tests the profitability of the "tested party"—typically the less complex party to the controlled transaction—against the profitability of comparable uncontrolled companies. The PLIs commonly used include operating margin, Berry ratio (ratio of gross profit to operating expenses), and return on assets.

In PPC's case, the CPM/TNMM analysis serves as a cross-check on PBI's overall profitability. Whitmore has identified 22 comparable companies for purposes of benchmarking PBI's operating margins. If PBI's profitability falls within the interquartile range of the comparable companies' PLIs, this provides additional support for the arm's-length nature of PPC's intercompany pricing.

3. Profit Split Method

The profit split method divides the combined operating profit (or loss) from controlled transactions according to the relative value of each party's contributions to the combined profit. See Treas. Reg. § 1.482-6. This method is most appropriate where both parties to the controlled transaction make unique and valuable contributions that cannot readily be benchmarked against uncontrolled comparables—a circumstance often present in transactions involving jointly developed intangible property.

The profit split method may be relevant to PPC's CSA in the event the IRS argues that PPC and PBI both make unique and valuable contributions to the development and exploitation of PPC's pharmaceutical IP. However, the CSA itself is designed as a cost-sharing mechanism that allocates development costs and returns based on RAB shares, and the regulations governing QCSAs (Treas. Reg. § 1.482-7) provide a specific framework for evaluating cost-sharing transactions that generally takes precedence over the general profit split method.

4. Income Method (for PCT Valuation)

The income method is specifically authorized under Treas. Reg. § 1.482-7(g)(4) for valuing platform contribution transactions in the context of qualified cost-sharing arrangements. The income method determines the arm's-length value of the pre-existing intangible property contributed to the CSA by discounting the anticipated future income attributable to that property at an appropriate discount rate—typically the weighted average cost of capital ("WACC").

The income method is the most commonly used method for PCT valuation where the intangible property at issue is unique and no comparable acquisition transactions are available. The method is conceptually straightforward but is highly sensitive to two key inputs: (a) the revenue projections used to estimate the future income stream attributable to the pre-existing intangibles, and (b) the discount rate used to convert that future income stream to a present value.

The income method is the method selected by PPC for the $312 million PCT valuation. As discussed in Section VII.C below, PPC employed a WACC of 9.8%, which reflects pharmaceutical-industry risk premiums and the specific risks associated with PPC's intangible property portfolio at the time of the CSA's effective date.

5. Unspecified Methods

Finally, the regulations permit the use of methods not specifically described in the regulations if such methods produce the most reliable arm's-length result. See Treas. Reg. § 1.482-4(d). The use of unspecified methods is relatively uncommon and is most likely to arise where the specified methods are inadequate to capture the unique economic characteristics of a particular transaction.

D. Application of Best Method Rule to PPC's Two Arrangements

1. Legacy IP Royalty — CUT Method

PPC's contemporaneous documentation applies the CUT method to the 4.5% legacy IP royalty rate, identifying comparable third-party pharmaceutical license agreements as the basis for determining the arm's-length royalty rate. The CUT method is the best method for this transaction for several reasons.

First, comparable pharmaceutical license agreements are identifiable. The pharmaceutical industry is characterized by a relatively robust market for technology licensing, in which companies routinely license patents, know-how, and regulatory filings to unrelated parties for commercialization in specific territories. This licensing activity generates a universe of comparable transactions from which arm's-length royalty rates can be derived. Whitmore Valuation Group has identified 14 such agreements that are sufficiently comparable to PPC's legacy IP license in terms of therapeutic area (oncology, immunology, or closely related fields), stage of development (approved or late-stage compounds), exclusivity (exclusive territorial licenses), geographic scope (comparable international territories), and functional profiles of the licensor and licensee.

Second, the comparability factors described in Treas. Reg. § 1.482-1(d) and § 1.482-4(c)(2) are sufficiently similar between PPC's legacy IP license and the identified CUT comparables. While no two pharmaceutical license agreements are identical, the differences between PPC's arrangement and the CUT comparables are of the type and magnitude that can be addressed through reliable comparability adjustments—adjustments to account for differences in contract terms, product maturity, geographic scope, and exclusivity.

Third, the CUT method provides a direct measure of the arm's-length royalty rate, without the need for the extensive modeling and projections required by alternative methods such as the income method or the profit split method. The CUT method is therefore less sensitive to data imperfections and subjective assumptions, making it the more reliable method under the circumstances.

The CUT analysis yields an interquartile range of 3.1% to 6.8%, with a median of 4.4%. PPC's 4.5% rate falls squarely within this range and is virtually at the median, providing strong support for the arm's-length nature of the legacy IP royalty rate.

2. CSA Cost-Sharing — Reasonably Anticipated Benefits Method

Under Treas. Reg. § 1.482-7(e), the share of intangible development activity costs borne by each participant in a qualified cost-sharing arrangement must be proportional to that participant's share of the reasonably anticipated benefits from the IDA. The RAB method is the prescribed regulatory method for determining cost-sharing ratios under a QCSA, and it is therefore the appropriate method for evaluating PPC's cost-sharing ratios.

PPC's RAB shares are calculated using prospective revenue projections for the Americas and non-Americas territories, which is one of several permitted bases for measuring RAB under the regulations. The revenue-based RAB approach is widely used in practice and has been accepted by the IRS and the Tax Court in prior cases. PPC's projections produced PBI RAB shares ranging from 38.2% in 2017 to 42.7% in 2020, reflecting the growth of PBI's non-Americas revenues relative to PPC's Americas revenues.

The IRS may challenge PPC's RAB projections on several grounds. First, the IRS may argue that PPC's ex ante revenue projections systematically understated non-Americas revenues, resulting in an RAB share that is too low and a corresponding underpayment of cost-sharing costs by PBI. Second, the IRS may argue that alternative RAB bases—such as operating profit rather than revenue—would produce higher PBI shares and would be more appropriate given the differences in profitability between the Americas and non-Americas territories. Third, the IRS may argue that the reasonableness of PPC's projections should be evaluated in light of actual outcomes, notwithstanding the general principle that RAB must be established prospectively based on reasonable expectations at the time the projections are made.

With respect to the IRS's burden on this issue, it is important to note that the IRS must demonstrate that PPC's RAB projections were unreasonable at the time they were made—not merely that they differed from actual results. The regulations contemplate that prospective RAB projections will not always match actual outcomes, and the occurrence of deviations between projected and actual revenues does not, by itself, establish that the projections were unreasonable. PPC should be prepared to support the reasonableness of its ex ante projections with contemporaneous business plans, board presentations, market analyses, and other documentation that was available at the time the projections were made.

3. PCT Valuation — Income Method/DCF

Under Treas. Reg. § 1.482-7(g), the PCT payment must reflect the arm's-length charge for the pre-existing intangible property contributed by a participant to the CSA. PPC used the income method, as described in Treas. Reg. § 1.482-7(g)(4), to value the pre-existing IP contributed to the CSA as of July 1, 2012. The income method is the most commonly used and most reliable method for PCT valuation where the intangible property at issue is unique and no comparable acquisition transactions exist from which a market-based valuation could be derived.

PPC's income method analysis employed a WACC of 9.8%, producing a PCT value of $312 million. Whitmore Valuation Group's independent analysis, using a range of reasonable assumptions for the discount rate and revenue projections, produces a range of $278 million to $361 million, within which PPC's $312 million payment falls.

The critical variable in the income method is the discount rate. PPC's WACC of 9.8% reflects pharmaceutical-industry risk premiums, including the beta of comparable pharmaceutical companies, the equity risk premium for the pharmaceutical sector, the size premium for companies of PPC's market capitalization, and the specific risk premium associated with the early-stage development uncertainty and regulatory risk inherent in PPC's intangible property portfolio at the time of the CSA's effective date.

The IRS may argue for a significantly lower discount rate—potentially as low as 7.2%, based on the preliminary indications from the examination team. The 260-basis-point difference between PPC's 9.8% WACC and the IRS's potential 7.2% WACC has a dramatic effect on the DCF output. All else being equal, a lower discount rate produces a higher present value of future income streams, which in turn produces a higher PCT valuation. Based on the IRS's internal analysis (as inferred from the examination team's preliminary IDR requests and the assignment of Dr. Washburne), the IRS may seek to inflate the PCT value to as high as $852 million—a figure that would represent a more than $540 million increase over PPC's $312 million payment and would generate a substantial § 482 adjustment.

The IRS may also challenge PPC's revenue projections, arguing that PPC underestimated the future revenue potential of the pre-existing intangibles at the time of the CSA's effective date. Additionally, the IRS may argue that PPC failed to include certain categories of intangible property in the PCT valuation—such as workforce in place, goodwill, customer relationships, and other residual intangibles—that should have been treated as pre-existing resources, capabilities, or rights contributed to the CSA.

PPC should direct Whitmore to prepare a rigorous WACC analysis using pharmaceutical-industry beta comparables, size premiums, and specific risk premium justifications. The analysis should also address the sensitivity of the DCF output to variations in the discount rate and revenue assumptions, demonstrating that PPC's $312 million payment is robust across a reasonable range of assumptions.

E. Burden of Proof Considera

PRIVILEGED & CONFIDENTIAL — ATTORNEY WORK PRODUCT
This memorandum is protected by the attorney-client privilege, the work product doctrine, and all other applicable privileges. It is prepared in anticipation of litigation and reflects the mental impressions, conclusions, opinions, and legal theories of attorneys at Calderwood & Harkness LLP. This memorandum and its contents shall not be disclosed to any person or entity outside the attorney-client relationship without the prior written consent of Calderwood & Harkness LLP and Penterra Pharmaceuticals Corp.
CALDERWOOD & HARKNESS LLP 1100 Connecticut Avenue, N.W., Suite 1400 Washington, D.C. 20036 Telephone: (202) 555-8200 Facsimile: (202) 555-8201
MEMORANDUM
TO: Leonard Cross, Responsible Partner, Tax Department Sylvia Hartwell, Billing Partner, Tax Department
FROM: Leila Nazari, Working Associate, Tax Department Garrett Simmons, Lead Associate, Tax Department
DATE: July 20, 2022
RE: Legal Analysis — IRC § 482 Arm's-Length Standard and Best Method Rule: Framework for Evaluating Penterra Pharmaceuticals Corp. Transfer Pricing Methodologies
MATTER NO.: 1018-00009
CLIENT: Penterra Pharmaceuticals Corp. (EIN: 22-3741856)
TAX YEARS AT ISSUE: 2017, 2018, 2019, 2020
IRS EXAM TEAM ID: LB&I-NE-TP-2022-00641
Right-click to update Table of Contents
I. Executive Summary
The purpose of this memorandum is to provide a comprehensive legal framework for evaluating the transfer pricing positions of Penterra Pharmaceuticals Corp. ("PPC" or the "Company") in connection with the examination initiated by the Internal Revenue Service Large Business & International Division ("LB&I"). On May 16, 2022, the IRS issued Letter 2205-A to PPC, formally opening an examination of the Company's federal income tax returns for tax years 2017 through 2020. The central focus of the examination is the intercompany transfer pricing methodology used between PPC's U.S. operations and its Irish subsidiary, Penterra Biopharma International DAC ("PBI"), through which PPC conducts a substantial portion of its non-Americas pharmaceutical commercialization activities.
Two principal intercompany arrangements are under scrutiny. First, the cost-sharing arrangement ("CSA"), effective July 1, 2012, under which PPC and PBI share the costs and risks associated with the development of pharmaceutical intangibles, and which included a platform contribution transaction ("PCT") payment of $312 million made by PBI to PPC as a buy-in to PPC's pre-existing intangible property portfolio. Second, the legacy intellectual property royalty arrangement, under which PBI licenses certain pre-2012 vintage pharmaceutical compounds from PPC at a royalty rate of 4.5% of net sales for non-Americas territories.
This memorandum analyzes the following legal and regulatory authorities as they apply to PPC's arrangements:
(a) The arm's-length standard under IRC § 482 and Treas. Reg. § 1.482-1(b), which governs the determination of taxable income among commonly controlled entities;
(b) The best method rule under Treas. Reg. § 1.482-1(c), which requires that the transfer pricing method producing the most reliable measure of an arm's-length result be applied;
(c) The specific methods applicable to intangible property transfers under Treas. Reg. § 1.482-4, including the comparable uncontrolled transaction ("CUT") method, the comparable profits method ("CPM"), the profit split method, and the income method;
(d) The cost-sharing arrangement requirements under Treas. Reg. § 1.482-7, including the provisions governing platform contribution transactions and the determination of reasonably anticipated benefits; and
(e) Key judicial precedent, including Altera Corp. v. Commissioner, 941 F.3d 1200 (9th Cir. 2019); Harborview Corporation, Inc. v. Commissioner, 147 T.C. 35 (2016), remanded, 900 F.3d 610 (8th Cir. 2018); and Hollowell & Co. v. Commissioner, 148 T.C. 108 (2017).
Based on the analysis set forth herein, we conclude that PPC's CSA cost-sharing ratios (ranging from 38.2% to 42.7% for tax years 2017 through 2020), the PCT valuation of $312 million, and the legacy IP royalty rate of 4.5% are defensible under the arm's-length standard and the best method analysis. The CUT method analysis yields an interquartile range of 3.1% to 6.8% (median of 4.4%) for comparable pharmaceutical license agreements, and PPC's 4.5% rate falls squarely within that range. The income method/Discounted cash flow ("DCF") analysis supports a PCT valuation range of $278 million to $361 million, within which PPC's $312 million payment is comfortably situated. The cost-sharing ratios, premised on reasonably anticipated benefits ("RAB") measured by prospective revenue projections, are consistent with the requirements of Treas. Reg. § 1.482-7(e).
Notwithstanding the defensibility of PPC's positions, this memorandum identifies specific areas of potential IRS challenge, including the selection criteria for CUT comparables, the discount rate employed in the PCT DCF valuation, the reasonableness of PPC's ex ante RAB projections, and PBI's economic substance and control over development, enhancement, maintenance, protection, and exploitation ("DEMPE") functions. We provide recommendations for bolstering PPC's positions in anticipation of these challenges, including directions for the economic analyses to be performed by Whitmore Valuation Group LLC under our Kovel engagement.
II. Scope and Background
A. Engagement Context
Calderwood & Harkness LLP was engaged by Penterra Pharmaceuticals Corp. on June 2, 2022, as outside tax counsel to represent and defend PPC in connection with the IRS examination of its federal income tax returns for tax years 2017, 2018, 2019, and 2020. The engagement letter, executed by PPC's Senior Vice President and General Tax Counsel, Rebecca Thornton, provides for Calderwood & Harkness to serve as lead counsel in all matters relating to the IRS examination, including the preparation and filing of responses to Information Document Requests ("IDRs"), the development of transfer pricing defense strategy, the engagement and supervision of experts, and, if necessary, the representation of PPC in administrative appeals, competent authority proceedings, or Tax Court litigation.
The IRS examination was opened on May 16, 2022, by Supervisory Revenue Agent Gerald Meskill, assigned to the LB&I Northeast Transfer Pricing Practice. The lead Revenue Agent on the examination is Patricia Dunleavy, a seasoned examiner with significant experience in pharmaceutical transfer pricing matters. Notably, the IRS has assigned two additional subject-matter specialists to the examination: Dr. Alan Washburne, an economist with the IRS Transfer Pricing Practice who is expected to lead the Service's economic analysis of PPC's intercompany pricing, and Attorney-Advisor Franklin Rosario of the IRS Office of Chief Counsel, International Division, who will provide legal guidance to the examination team. The assignment of both an economist and an attorney-advisor at this early stage of the examination signals the IRS's intent to devote substantial resources to challenging PPC's transfer pricing positions.
PPC was not enrolled in the IRS Compliance Assurance Process ("CAP") for any of the tax years at issue. As a result, PPC's transfer pricing positions were not pre-reviewed or pre-approved by the IRS prior to the filing of its returns for 2017 through 2020. This distinguishes PPC from several of its pharmaceutical-industry peers that have participated in CAP and resolved transfer pricing issues prospectively.
On June 20, 2022, Calderwood & Harkness executed a Kovel engagement letter with Whitmore Valuation Group LLC, designating Dr. Helena Vasquez, Managing Director and Lead Economist, as the firm's lead economic expert for purposes of the examination. The Kovel engagement is structured to ensure that all communications between Whitmore, Calderwood & Harkness, and PPC are protected under the attorney-client privilege and the work product doctrine, consistent with the framework established in United States v. Kovel, 296 F.2d 918 (2d Cir. 1961). Dr. Vasquez brings more than twenty years of experience in pharmaceutical transfer pricing and has served as a testifying expert in multiple Tax Court proceedings involving § 482 disputes.
B. PPC's Global Corporate Structure
An understanding of PPC's corporate structure is essential to the transfer pricing analysis, as the structure defines the controlled relationships at issue and the allocation of functions, assets, and risks among the entities.
Penterra Pharmaceuticals Corp. ("PPC") is a Delaware corporation, publicly traded on the Nasdaq Global Select Market under the ticker symbol PPCA, with its principal executive offices located at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. PPC is a specialty pharmaceutical and biotechnology company focused on three primary therapeutic areas: oncology, immunology, and rare-disease therapeutics. For fiscal year 2020, PPC reported consolidated revenue of approximately $6.82 billion, pre-tax income of approximately $1.47 billion, and employed approximately 14,500 individuals worldwide. PPC maintains its primary research and development operations in Princeton Junction and at satellite laboratories in Cambridge, Massachusetts, and San Diego, California. PPC's U.S. commercial operations are responsible for the marketing and distribution of PPC's pharmaceutical products throughout the Americas region, defined under the CSA as North America, Central America, South America, and the Caribbean.
Penterra Holdings Luxembourg S.à r.l. ("PHL") is a société à responsabilité limitée organized under the laws of the Grand Duchy of Luxembourg (Registre de Commerce et des Sociétés No. B 168452), with its registered office at 14, rue Aldringen, L-1118 Luxembourg. PHL is 100% owned by PPC. PHL is treated as a disregarded entity for U.S. federal income tax purposes under Treas. Reg. § 301.7701-3, and accordingly, all transactions between PHL and PBI, or between PHL and PPC, are treated for U.S. tax purposes as transactions directly between PPC and PBI. PHL's function in the corporate structure is primarily as an intermediate holding entity, and it does not conduct any substantive operational activities.
Penterra Biopharma International DAC ("PBI") is a Designated Activity Company organized under Irish law, with its registered office at 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland (Irish Tax Reference: 3218764T). PBI is 100% owned by PHL (and thus, through the disregarded-entity treatment, is treated for U.S. tax purposes as owned directly by PPC). PBI functions as the intellectual property holding company and commercial principal for PPC's pharmaceutical products outside the Americas. PBI holds the rights to develop and exploit PPC's pharmaceutical IP portfolio for non-Americas territories pursuant to the CSA, and licenses certain pre-2012 legacy compounds from PPC under the legacy IP royalty arrangement. For fiscal year 2020, PBI reported revenue of approximately €2.14 billion and pre-tax income of approximately €1.06 billion. PBI has grown substantially since its incorporation in March 2012, from 52 employees at inception to approximately 185 employees as of December 31, 2020. PBI's Managing Director is Aidan Naughton, who operates from PBI's Dublin headquarters and oversees all non-Americas commercial operations. PBI is subject to the standard Irish corporate income tax rate of 12.5% on trading income. Beginning in fiscal year 2016, PBI has also availed itself of Ireland's Knowledge Development box ("KDB") regime, which provides an effective tax rate of 6.25% on qualifying income derived from qualifying assets, including patented pharmaceutical compounds.
Penterra Manufacturing Ireland Ltd. ("PMI") is an Irish private limited company (Companies Registration Office No. 512347), with its registered office at Unit 7, Ringaskiddy Industrial Estate, Co. Cork T12 PX29, Ireland. PMI is 100% owned by PBI and operates as a contract manufacturer of oncology and immunology biologic products for non-Americas markets. PMI manufactures under a cost-plus arrangement with PBI, earning a markup of cost plus 8%, which is consistent with the contract manufacturing benchmarking analysis included in PPC's contemporaneous transfer pricing documentation. PMI employs approximately 620 individuals at its Cork manufacturing facility, which includes a state-of-the-art biologics production suite and quality assurance laboratory.
C. The Intercompany Arrangements at Issue
The IRS examination focuses on two intercompany arrangements between PPC and PBI. Each arrangement involves the transfer, license, or shared development of intangible property, and each is subject to the arm's-length standard under IRC § 482 and the associated Treasury Regulations.
1. Cost-Sharing Arrangement (CSA)
The CSA was executed effective July 1, 2012, between PPC and PBI (through PHL, disregarded). Under the CSA, PBI acquired the right to develop and exploit PPC's pharmaceutical IP portfolio outside the Americas—defined to encompass all territories other than North America, Central America, South America, and the Caribbean—in exchange for: (a) a lump-sum PCT payment of $312 million, representing the fair value of PPC's pre-existing intangible property contributed to the CSA (primarily clinical-stage and approved oncology compounds); and (b) ongoing cost-sharing payments proportional to each participant's reasonably anticipated benefits from the intangible development activities ("IDA") conducted under the CSA.
PCT Payment. The $312 million lump-sum PCT payment was made by PBI to PPC on July 1, 2012. The payment was calculated using the income method described in Treas. Reg. § 1.482-7(g)(4), which involves discounting the anticipated future income attributable to the pre-existing intangible property at an appropriate discount rate. PPC employed a weighted average cost of capital ("WACC") of 9.8% in the DCF analysis, reflecting pharmaceutical-industry risk premiums, the early-stage development uncertainty associated with clinical-stage compounds, and the regulatory risks inherent in obtaining marketing approvals across multiple global jurisdictions. The $312 million figure represents a single point estimate within what Whitmore Valuation Group has confirmed is an arm's-length range of $278 million to $361 million.
Cost-Sharing Ratios (2017–2020). Under the CSA, each participant's share of the annual qualified research and development costs is determined based on its RAB share, which is recalculated annually based on prospective revenue projections for the Americas and non-Americas territories. For the tax years at issue, PBI's RAB share and corresponding cost-sharing payments were as follows:
The gradual increase in PBI's RAB share from 38.2% to 42.7% over the four-year period reflects PBI's expanding non-Americas market penetration, which in turn reflects PBI's successful commercialization efforts in European, Asia-Pacific, and other international markets. The increase is consistent with actual revenue trends, as PBI's non-Americas net sales grew proportionately relative to PPC's Americas net sales over this period.
2. Legacy IP Royalty Arrangement
Separate from the CSA, PBI licensed certain pre-2012 vintage legacy compounds from PPC pursuant to a formal license agreement executed contemporaneously with the CSA. The legacy IP royalty arrangement covers pharmaceutical compounds that were fully developed and commercialized prior to the effective date of the CSA and that were not contributed to the CSA's intangible development program. Under the license, PBI pays PPC a royalty of 4.5% of net sales for non-Americas territories. The royalty rate was determined on the basis of a CUT analysis identifying comparable pharmaceutical license agreements between unrelated parties.
Legacy compound non-Americas net sales and royalty payments for the tax years at issue were as follows:
The declining trajectory of legacy compound net sales is consistent with the natural lifecycle of mature pharmaceutical products, as newer compounds developed under the CSA increasingly capture market share and as certain legacy compounds face generic competition in key international markets.
3. Key Products
PPC's product portfolio includes several significant pharmaceutical products that generate substantial global revenues. The three most commercially significant products are:
Veritaxol — PPC's oncology blockbuster. Veritaxol is a monoclonal antibody indicated for the treatment of advanced non-small cell lung cancer and metastatic colorectal cancer. For fiscal year 2020, Veritaxol generated global net sales of approximately $3.12 billion, of which approximately $1.34 billion was attributable to non-Americas territories. Veritaxol is PPC's single largest revenue-generating product and is at the center of the CSA's commercial significance.
Imvara — PPC's immunology franchise product. Imvara is a biologic therapy approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and moderate-to-severe plaque psoriasis. For fiscal year 2020, Imvara generated global net sales of approximately $1.87 billion, with approximately $0.79 billion attributable to non-Americas territories.
Cerulon — PPC's rare-disease product. Cerulon is an enzyme replacement therapy for the treatment of a rare lysosomal storage disorder. For fiscal year 2020, Cerulon generated global net sales of approximately $0.62 billion, with approximately $0.28 billion attributable to non-Americas territories.
4. Contemporaneous Transfer Pricing Documentation
PPC's contemporaneous transfer pricing documentation for all four tax years at issue (2017, 2018, 2019, and 2020) was prepared by Crestfield & Associates LLP, under the supervision of Susan Lam, Transfer Pricing Partner. The documentation was prepared to meet the standards set forth in IRC § 6662(e) and the associated regulations for penalty protection purposes. The documentation includes, for each tax year, a comprehensive functional analysis, a description of the intercompany transactions, an evaluation of the available transfer pricing methods under the best method rule, a detailed benchmarking analysis identifying comparable uncontrolled transactions (for the royalty) and comparable companies (for CPM/TNMM profitability testing), and a conclusion as to the arm's-length nature of PPC's intercompany pricing. The existence and quality of this contemporaneous documentation is a significant factor in PPC's defense against potential IRS adjustments and penalty exposure.
D. Purpose of This Memorandum
This memorandum is intended to accomplish the following objectives:
(1) Establish the legal framework governing the arm's-length standard under IRC § 482 and its implementing regulations, with particular emphasis on the provisions applicable to controlled transfers of intangible property and cost-sharing arrangements;
(2) Apply the best method rule, as articulated in Treas. Reg. § 1.482-1(c), to PPC's chosen transfer pricing methods—specifically, the CUT method for the legacy IP royalty, the income method/DCF for the PCT valuation, and the RAB-based method for the CSA cost-sharing ratios—and evaluate whether these methods satisfy the requirements for producing the most reliable arm's-length result;
(3) Survey the controlling judicial precedent, including the Ninth Circuit's decision in Altera, the Tax Court and Eighth Circuit decisions in Harborview Corporation, and the Tax Court's decision in Penmark Holdings, and assess their implications for PPC's positions;
(4) Identify the potential arguments that the IRS examination team—including Dr. Washburne and Attorney-Advisor Rosario—may raise in challenging PPC's transfer pricing positions, and assess the strength and vulnerability of those arguments;
(5) Provide a foundation for the independent economic analyses to be performed by Whitmore Valuation Group LLC (Dr. Vasquez) under the Kovel arrangement, and for the development of PPC's IDR response strategy; and
(6) Serve as a predicate for the series of companion memoranda that will address specific aspects of PPC's transfer pricing defense in greater detail, as outlined in Appendix C to this memorandum.
III. Statutory Framework: IRC § 482
A. Text and Purpose of IRC § 482
Section 482 of the Internal Revenue Code provides the statutory authority for the Secretary of the Treasury, acting through the Internal Revenue Service, to allocate gross income, deductions, credits, or allowances among two or more organizations, trades, or businesses that are owned or controlled, directly or indirectly, by the same interests. The statute provides, in relevant part:
"In any case of two or more organizations, trades, or businesses (whether or not incorporated, whether or not organized in the United States, and whether or not affiliated) owned or controlled directly or indirectly by the same interests, the Secretary may distribute, apportion, or allocate gross income, deductions, credits, or allowances between or among such organizations, trades, or businesses, if he determines that such distribution, apportionment, or allocation is necessary in order to prevent evasion of taxes or clearly to reflect the income of any of such organizations, trades, or businesses."
The language of § 482 is intentionally broad in scope, and the requirement of common ownership or control is satisfied by a wide range of relationships. In PPC's case, the common control requirement is unambiguously met: PPC directly owns 100% of PHL, which in turn directly owns 100% of PBI. Because PHL is treated as a disregarded entity for U.S. federal income tax purposes under the check-the-box regulations of Treas. Reg. § 301.7701-3, PBI is treated for all § 482 purposes as directly controlled by PPC. There is no dispute between PPC and the IRS as to the existence of common control, and the threshold jurisdictional requirement of § 482 is clearly satisfied.
The purpose of § 482 has been articulated by courts and the Treasury Department in two complementary formulations. First, § 482 serves to place a controlled taxpayer on a tax parity with an uncontrolled taxpayer by determining the true taxable income from the property and business of each entity in the controlled group. See Treas. Reg. § 1.482-1(a)(1). The regulation states that the purpose is to "ensure that taxpayers clearly reflect income attributable to controlled transactions, and to prevent the avoidance of taxes with respect to such transactions." Second, and relatedly, § 482 serves to prevent the artificial shifting of income between commonly controlled entities that might otherwise exploit differences in tax rates across jurisdictions. This purpose is particularly relevant in PPC's case, where the U.S. corporate tax rate (35% for tax year 2017 and 21% for tax years 2018–2020 following the Tax Cuts and Jobs Act) significantly exceeds the Irish corporate tax rate of 12.5% on trading income (and the Knowledge Development box rate of 6.25% on qualifying income), creating a natural incentive for income-shifting from the United States to Ireland.
It is critical to note, however, that § 482 is not a penal statute. As the Tax Court has repeatedly emphasized, the allocation authority under § 482 is corrective in nature, designed to ensure that controlled transactions produce results consistent with the arm's-length standard rather than to punish taxpayers for engaging in intercompany transactions. See, e.g., Commissioner v. First Security Bank of Utah, 405 U.S. 394, 400 (1972); B. Forman Co. v. Commissioner, 453 F.2d 1144, 1151 (2d Cir. 1972). The IRS's authority under § 482 is not unlimited; it is constrained by the requirement that any allocation must reflect an arm's-length result, and the IRS cannot reallocate income in a manner that exceeds what would have resulted from dealings between uncontrolled parties acting at arm's length.
A significant contextual consideration for PPC's examination is the change in the U.S. corporate tax rate brought about by the TCJA, which reduced the rate from 35% to 21% effective January 1, 2018. For tax year 2017 (the only pre-TCJA year at issue), the 35% U.S. rate created a 22.5 percentage-point differential relative to Ireland's 12.5% rate, while for tax years 2018–2020, the post-TCJA differential narrowed to 8.5 percentage points (or 14.75 percentage points relative to the 6.25% KDB rate). The larger pre-TCJA differential increases the IRS's incentive to challenge income-shifting arrangements for 2017, as the tax effect of any § 482 adjustment is correspondingly larger for that year.
B. The Arm's-Length Standard — Treas. Reg. § 1.482-1(b)
The arm's-length standard is the foundational principle governing all allocations and adjustments under IRC § 482. Treasury Regulation § 1.482-1(b)(1) provides:
"In determining the true taxable income of a controlled taxpayer, the standard to be applied in every case is that of a taxpayer dealing at arm's length with an uncontrolled taxpayer. A controlled transaction meets the arm's length standard if the results of the transaction are consistent with the results that would have been realized if uncontrolled taxpayers had engaged in the same transaction under the same circumstances (arm's length result)."
The arm's-length standard thus requires a comparison between the terms and results of controlled transactions and those that would have been achieved in comparable transactions between independent parties. The standard does not require that controlled parties actually mirror specific transactions between unrelated parties; rather, it requires that the economic outcomes of controlled transactions be consistent with the range of outcomes that arm's-length parties would have achieved under comparable circumstances.
The regulation further provides that the arm's-length standard is generally applied on a transaction-by-transaction basis. See Treas. Reg. § 1.482-1(b)(2)(i). However, the regulations recognize that in certain cases, two or more transactions may be so interrelated that they should be aggregated and evaluated together. This aggregation principle may be relevant to PPC's arrangements, where the CSA and the legacy IP royalty arrangement collectively define the economic relationship between PPC and PBI with respect to PPC's pharmaceutical IP portfolio. Nevertheless, the two arrangements involve distinct categories of intangible property (post-2012 CSA-developed IP versus pre-2012 legacy IP) and are governed by separate contractual instruments, supporting their treatment as separate transactions for arm's-length analysis purposes.
Central to the arm's-length standard is the concept of comparability. To determine whether a controlled transaction produces an arm's-length result, it is necessary to identify comparable uncontrolled transactions and to compare the controlled and uncontrolled transactions on the basis of their economically relevant characteristics. The comparability analysis is discussed in detail in Section III.C below.
The regulations also establish the concept of the arm's-length range, which recognizes that the application of a transfer pricing method typically does not produce a single arm's-length price or result but rather a range of prices or results, any of which could reasonably have been achieved by uncontrolled parties. Where a controlled transaction falls within the arm's-length range, no adjustment is warranted. Where it falls outside the range, the IRS may adjust the controlled taxpayer's income to bring it within the range. The arm's-length range is discussed in detail in Section III.D below.
C. Comparability Factors — Treas. Reg. § 1.482-1(d)
The reliability of any transfer pricing analysis depends fundamentally on the quality of the comparability analysis. Treasury Regulation § 1.482-1(d) identifies a non-exhaustive set of factors that must be considered in evaluating the comparability of controlled and uncontrolled transactions. These factors are applicable across all transfer pricing methods and are critical to assessing the reliability of PPC's selected methods.
1. Functions Performed
The functional analysis is the starting point of any transfer pricing comparability assessment. Treas. Reg. § 1.482-1(d)(3)(i) requires consideration of the functions performed by each party to the controlled transaction, the assets employed, and the risks assumed. The functional analysis establishes the economic profile of each party and determines the appropriate characterization of the transaction for purposes of method selection and comparability.
In PPC's case, the functional analysis is of critical importance because the IRS may argue that the key DEMPE functions—development, enhancement, maintenance, protection, and exploitation—with respect to PPC's pharmaceutical IP portfolio were performed primarily by PPC's U.S.-based personnel, notwithstanding PBI's formal role as IP-holding company and non-Americas commercial principal. PBI's functional profile must therefore be carefully documented. As discussed in Section VII below, PBI employs 185 individuals (as of December 31, 2020), conducts independent commercial decision-making through its Dublin-based management team led by Managing Director Aidan Naughton, exercises independent pricing authority across 68 country markets, has conducted 42 board meetings during 2017–2020 (all held in Dublin), has incurred cumulative regulatory expenditures of €47.2 million, operates from approximately 18,000 square feet of office space in Dublin, and maintains independent banking relationships with Glenmore Bank Ireland plc. These facts are essential to establishing PBI's economic substance and its right to retain income commensurate with the functions it performs, the assets it employs, and the risks it assumes.
2. Contractual Terms
Treas. Reg. § 1.482-1(d)(3)(ii) provides that arm's-length parties typically formalize their dealings in contracts that reflect the economic substance of their arrangement. The regulations recognize that contract terms—including provisions regarding payment, duration, termination, volume, and scope of rights—can materially affect the pricing of a transaction and must be considered in the comparability analysis.
PPC has both a formal CSA agreement (executed July 1, 2012) and a formal legacy IP license agreement (executed contemporaneously). Both agreements were prepared with the assistance of outside counsel and reflect the commercially negotiated terms between PPC and PBI, including provisions addressing territorial scope, exclusivity, cost allocation, payment terms, dispute resolution, and termination. The existence of comprehensive written agreements is a positive factor in PPC's defense, as it demonstrates that the intercompany arrangements were structured with the formality and deliberateness characteristic of arm's-length dealings.
The regulations further provide, however, that the contractual terms of a controlled transaction must be consistent with the economic substance of the parties' actual conduct. See Treas. Reg. § 1.482-1(d)(3)(ii)(B). If the actual conduct of the parties is inconsistent with the contractual terms, the IRS may disregard the contract and recharacterize the transaction based on the economic substance of the parties' actual conduct. This principle is discussed further in connection with the "actual conduct" principle in Section III.C.5 below.
3. Risks Assumed
Treas. Reg. § 1.482-1(d)(3)(iii) requires consideration of the risks assumed by each party to the controlled transaction. Risk allocation is a critical factor in the comparability analysis because the assumption of economically significant risks is a key driver of profit potential. A party that bears greater risk is generally entitled to greater compensation.
In PPC's case, PBI bears significant risks in connection with its role as non-Americas commercial principal, including: (a) market risk associated with the commercialization of PPC's pharmaceutical products across diverse and heterogeneous international markets; (b) regulatory risk associated with obtaining and maintaining marketing approvals from regulatory authorities in 68 country markets; (c) pricing risk, as PBI independently sets prices and negotiates with payors, governments, and distributors in each country; (d) credit risk associated with sales to distributors and healthcare institutions in international markets; (e) foreign currency risk, as PBI's revenue is denominated in multiple currencies while its cost-sharing payments to PPC are denominated in U.S. dollars; and (f) development risk under the CSA, as PBI shares in the costs and outcomes of PPC's intangible development activities without any guarantee that such activities will produce commercially successful products.
The IRS may argue that PBI's risk assumption is nominal or that the risks are effectively managed and controlled by PPC's U.S.-based operations. PPC must be prepared to demonstrate, through documentary evidence and witness testimony, that PBI exercises genuine independent decision-making authority with respect to the risks it bears, consistent with the risk analysis framework established in the OECD Transfer Pricing Guidelines (2017), Chapter I.
4. Economic Conditions
Treas. Reg. § 1.482-1(d)(3)(iv) requires consideration of the economic conditions prevailing in the markets in which the controlled and uncontrolled transactions take place. Relevant economic conditions include market size, level of competition, availability of substitute goods or services, purchasing power, regulatory environment, and geographic location.
The pharmaceutical industry presents unique economic conditions that must be reflected in the comparability analysis. Pharmaceutical products are characterized by long development timelines (often 10–15 years from discovery to market), extensive regulatory requirements, significant development costs and failure rates, patent protection and exclusivity periods, geographic variability in pricing and reimbursement regimes, and the periodic impact of generic and biosimilar competition upon patent expiration. These industry-specific characteristics affect both the selection of comparables and the economic assumptions underlying PPC's transfer pricing methods.
5. Property or Services Transferred
Treas. Reg. § 1.482-1(d)(3)(v) requires consideration of the nature of the property or services transferred in the controlled transaction. In PPC's case, the property at issue consists of pharmaceutical intangible property—specifically, patents, trade secrets, know-how, clinical data, regulatory filings and approvals, and associated rights relating to PPC's oncology, immunology, and rare-disease therapeutic compounds. Pharmaceutical intangibles are highly specialized and differentiated, and their value is driven by factors such as the stage of clinical development, the breadth and quality of the patent portfolio, the competitive landscape, the size of the addressable patient population, and the anticipated duration of market exclusivity.
The specialized and differentiated nature of pharmaceutical intangibles is relevant to the best method analysis because it affects the availability and reliability of comparables. As discussed in Section IV below, truly comparable uncontrolled transactions involving pharmaceutical intangibles of similar nature, scope, and stage of development may be limited, which in turn affects the reliability of the CUT method and may support the use of alternative methods such as the income method or the profit split method.
6. Actual Conduct Principle
The regulations emphasize that the economic substance of a transaction, not merely its legal form, controls the transfer pricing analysis. Treas. Reg. § 1.482-1(d)(3)(ii)(B) provides that where the actual conduct of the parties is inconsistent with the written terms of their agreement, the IRS may disregard the contractual provisions and determine the true terms of the transaction based on the parties' actual conduct. This "actual conduct" principle is a powerful tool in the IRS's arsenal, as it enables the Service to look beyond formal contractual arrangements and assess whether the economic reality of the controlled relationship matches the allocation of income reflected in the taxpayer's transfer pricing.
For PPC, the actual conduct principle underscores the importance of ensuring that PBI's real-world activities, decision-making authority, and risk management are consistent with its contractual role as IP-holding company and non-Americas commercial principal. Any disconnect between PBI's formal responsibilities under the CSA and license agreement, on the one hand, and its actual day-to-day activities and decision-making processes, on the other, could provide the IRS with a basis for recharacterizing the intercompany arrangements and reallocating income to PPC.
D. Arm's-Length Range — Treas. Reg. § 1.482-1(e)
The arm's-length range is a critical concept in the application of any transfer pricing method. Treasury Regulation § 1.482-1(e)(2) provides that where the application of a transfer pricing method produces a range of results from comparable uncontrolled transactions, the arm's-length range is established by the interquartile range—that is, the range of results from the 25th percentile to the 75th percentile—of the results.
If the controlled taxpayer's result falls within the interquartile range, the result is treated as arm's-length and no adjustment is warranted. If the controlled taxpayer's result falls outside the interquartile range, the IRS may adjust the taxpayer's income to a point within the range. Treas. Reg. § 1.482-1(e)(3) provides that, in such cases, the adjusted result is typically the median of the comparable results, though other points within the range may be appropriate depending on the facts and circumstances.
The interquartile range methodology applies to all transfer pricing methods, though the specific results and their distribution will vary depending on the method applied and the quality of the available comparables. For PPC, the application of the arm's-length range concept is relevant in two principal respects:
First, the CUT analysis for the legacy IP royalty rate yields an interquartile range of 3.1% to 6.8%, with a median of 4.4%. PPC's 4.5% rate falls within this range and is essentially at the median, providing strong support for PPC's position.
Second, the CPM/TNMM analysis of PBI's overall profitability, which serves as a cross-check on the reasonableness of PBI's income retention, will produce an interquartile range of operating margins or Berry ratios derived from comparable companies. PBI's actual profitability must fall within this range to be defensible.
The arm's-length range concept is also relevant to the PCT valuation. Whitmore Valuation Group's income method/DCF analysis produces a range of $278 million to $361 million, representing the sensitivity of the DCF output to reasonable variations in key assumptions (principally the discount rate and revenue projections). PPC's $312 million PCT payment falls within this range.
IV. The Best Method Rule — Treas. Reg. § 1.482-1(c)
A. Overview
The best method rule is the cornerstone of method selection under IRC § 482 and its implementing regulations. Treasury Regulation § 1.482-1(c) provides:
"The arm's length result of a controlled transaction must be determined under the method that, under the facts and circumstances, provides the most reliable measure of an arm's length result."
This deceptively simple formulation embodies a principle of considerable practical significance: there is no hierarchy of methods, and no single method is preferred as a matter of principle over any other. Rather, the best method for a particular controlled transaction depends on the specific facts and circumstances of that transaction, including the nature of the property or services at issue, the availability and quality of data, and the degree of comparability between the controlled and uncontrolled transactions being compared.
The absence of a formal hierarchy means that the taxpayer has flexibility in selecting its transfer pricing method, but it also means that the IRS has the authority to challenge the taxpayer's method selection if the Service can demonstrate that an alternative method would produce a more reliable arm's-length result. Conversely, if the taxpayer can demonstrate that its chosen method satisfies the best method rule, the IRS cannot simply substitute a different method merely because the alternative method produces a different (and higher) allocation of income to the United States.
Notwithstanding the absence of a formal hierarchy, the regulations observe that "if two or more applications of a single method provide inconsistent results, the relative reliability of each application must be determined in light of the quality of the data and the assumptions used in each application." Treas. Reg. § 1.482-1(c)(1). Moreover, the regulations note that where a CUT of high reliability is available—that is, where the comparable uncontrolled transaction is sufficiently similar in all material respects to the controlled transaction—the CUT method will typically be the best method because it provides the most direct measure of an arm's-length price. This observation is particularly relevant to PPC's legacy IP royalty analysis, where the question of whether PPC's CUT comparables are of sufficiently high reliability is likely to be a central point of contention with the IRS.
B. Factors in Determining the Best Method
The regulations identify three principal factors for determining which method provides the most reliable measure of an arm's-length result under the facts and circumstances:
1. Degree of Comparability
The first and most important factor is the degree of comparability between the controlled transaction and the uncontrolled transactions, comparables, or other data used in applying the method. The method that relies on the closest factual comparables—considering all of the comparability factors described in Treas. Reg. § 1.482-1(d) and discussed in Section III.C above—is generally the most reliable. See Treas. Reg. § 1.482-1(c)(2)(i).
The degree of comparability is affected by the number and magnitude of adjustments necessary to account for differences between the controlled and uncontrolled transactions. A method that requires fewer and smaller adjustments is, all else being equal, more reliable than a method that requires numerous or large adjustments, because each adjustment introduces the possibility of error and reduces the confidence that can be placed in the ultimate result.
For PPC's legacy IP royalty, the CUT method relies on 14 comparable pharmaceutical license agreements identified by Whitmore Valuation Group. The degree of comparability of these agreements to PPC's legacy IP license turns on the similarity of the intangibles (therapeutic area, stage of development, competitive position), the terms of the license (exclusivity, duration, territory), and the functions, assets, and risks of the licensor and licensee. If these agreements are sufficiently comparable—requiring only modest adjustments for identifiable differences—the CUT method will satisfy the best method rule. If, however, the IRS can identify material differences that cannot be reliably adjusted for, the CUT method's reliability may be undermined.
2. Quality of Data and Assumptions
The second factor is the quality of the data and assumptions used in applying the method. See Treas. Reg. § 1.482-1(c)(2)(ii). Methods that require fewer and more reliable assumptions produce more reliable results. For example, the CUT method, when highly comparable uncontrolled transactions are available, requires relatively few assumptions beyond the comparability adjustments themselves. In contrast, the income method for PCT valuation requires assumptions about future revenue growth rates, product life cycles, discount rates, tax rates, and terminal values, each of which introduces the possibility of error and subjective judgment.
The quality of data is also a function of the source and reliability of the information used. Publicly available data from arm's-length transactions between independent parties is generally considered more reliable than internal or estimated data. Similarly, contemporaneous data—data available at the time the controlled transaction was entered into—is generally more reliable than hindsight data when evaluating the reasonableness of the taxpayer's transfer pricing at the time it was established.
3. Sensitivity of Results to Deficiencies in Data and Assumptions
The third factor is the sensitivity of the method's results to deficiencies in the data or assumptions used. See Treas. Reg. § 1.482-1(c)(2)(iii). Some methods are inherently more sensitive than others to data imperfections. For example, the income method for PCT valuation is highly sensitive to the discount rate and revenue projection assumptions: small changes in the WACC or in the assumed growth rate of future revenues can produce dramatically different present values. As discussed in Section IV.D.3 below, the 260-basis-point difference between PPC's WACC of 9.8% and the IRS's potential WACC of 7.2% can produce a PCT valuation difference of hundreds of millions of dollars. Methods that are less sensitive to data imperfections are, all else being equal, more reliable.
Conversely, the CUT method, when applied to closely comparable transactions, is relatively insensitive to small data imperfections because it relies directly on observed arm's-length prices rather than on modeled or projected financial data. This relative insensitivity is one of the reasons the regulations suggest that a CUT of high reliability will typically be the best method.
C. Available Methods for Intangible Property — Treas. Reg. § 1.482-4
Treasury Regulation § 1.482-4 prescribes the specific methods available for determining the arm's-length charge for controlled transfers of intangible property. The regulations provide four specified methods and one catch-all provision for unspecified methods:
1. Comparable Uncontrolled Transaction (CUT) Method
The CUT method evaluates whether the amount charged in a controlled transfer of intangible property is arm's-length by reference to the amount charged in comparable uncontrolled transactions involving the transfer of the same or comparable intangible property under comparable circumstances. See Treas. Reg. § 1.482-4(c).
The CUT method is the most direct method for determining an arm's-length royalty rate because it compares the controlled transaction to actual arm's-length transactions between unrelated parties. When highly comparable CUTs are available, this method provides the most reliable measure of an arm's-length result and will typically satisfy the best method rule.
The application of the CUT method requires a detailed comparability analysis, focusing on factors including: (i) the similarity of the intangible property transferred (including its type, stage of development, expected profitability, and exclusivity); (ii) the terms of the license or transfer (including royalty base, payment schedule, and duration); (iii) the territorial scope of the rights transferred; (iv) the exclusivity of the rights; and (v) the functional profiles of the parties. See Treas. Reg. § 1.482-4(c)(2).
The CUT method is the method selected by PPC for its legacy IP royalty arrangement. As discussed in Section VII.A below, PPC's contemporaneous documentation and Whitmore's independent analysis identify 14 comparable pharmaceutical license agreements that support an interquartile range of 3.1% to 6.8% and a median of 4.4%, within which PPC's 4.5% rate falls.
2. Comparable Profits Method (CPM)
The comparable profits method evaluates whether the amount charged in a controlled transaction is arm's-length based on objective measures of profitability (profit level indicators or "PLIs") derived from uncontrolled taxpayers that engage in comparable activities under comparable circumstances. See Treas. Reg. § 1.482-5. The CPM corresponds to the Transactional Net Margin Method ("TNMM") used under the OECD Transfer Pricing Guidelines.
The CPM is a one-sided method that tests the profitability of the "tested party"—typically the less complex party to the controlled transaction—against the profitability of comparable uncontrolled companies. The PLIs commonly used include operating margin, Berry ratio (ratio of gross profit to operating expenses), and return on assets.
In PPC's case, the CPM/TNMM analysis serves as a cross-check on PBI's overall profitability. Whitmore has identified 22 comparable companies for purposes of benchmarking PBI's operating margins. If PBI's profitability falls within the interquartile range of the comparable companies' PLIs, this provides additional support for the arm's-length nature of PPC's intercompany pricing.
3. Profit Split Method
The profit split method divides the combined operating profit (or loss) from controlled transactions according to the relative value of each party's contributions to the combined profit. See Treas. Reg. § 1.482-6. This method is most appropriate where both parties to the controlled transaction make unique and valuable contributions that cannot readily be benchmarked against uncontrolled comparables—a circumstance often present in transactions involving jointly developed intangible property.
The profit split method may be relevant to PPC's CSA in the event the IRS argues that PPC and PBI both make unique and valuable contributions to the development and exploitation of PPC's pharmaceutical IP. However, the CSA itself is designed as a cost-sharing mechanism that allocates development costs and returns based on RAB shares, and the regulations governing QCSAs (Treas. Reg. § 1.482-7) provide a specific framework for evaluating cost-sharing transactions that generally takes precedence over the general profit split method.
4. Income Method (for PCT Valuation)
The income method is specifically authorized under Treas. Reg. § 1.482-7(g)(4) for valuing platform contribution transactions in the context of qualified cost-sharing arrangements. The income method determines the arm's-length value of the pre-existing intangible property contributed to the CSA by discounting the anticipated future income attributable to that property at an appropriate discount rate—typically the weighted average cost of capital ("WACC").
The income method is the most commonly used method for PCT valuation where the intangible property at issue is unique and no comparable acquisition transactions are available. The method is conceptually straightforward but is highly sensitive to two key inputs: (a) the revenue projections used to estimate the future income stream attributable to the pre-existing intangibles, and (b) the discount rate used to convert that future income stream to a present value.
The income method is the method selected by PPC for the $312 million PCT valuation. As discussed in Section VII.C below, PPC employed a WACC of 9.8%, which reflects pharmaceutical-industry risk premiums and the specific risks associated with PPC's intangible property portfolio at the time of the CSA's effective date.
5. Unspecified Methods
Finally, the regulations permit the use of methods not specifically described in the regulations if such methods produce the most reliable arm's-length result. See Treas. Reg. § 1.482-4(d). The use of unspecified methods is relatively uncommon and is most likely to arise where the specified methods are inadequate to capture the unique economic characteristics of a particular transaction.
D. Application of Best Method Rule to PPC's Two Arrangements
1. Legacy IP Royalty — CUT Method
PPC's contemporaneous documentation applies the CUT method to the 4.5% legacy IP royalty rate, identifying comparable third-party pharmaceutical license agreements as the basis for determining the arm's-length royalty rate. The CUT method is the best method for this transaction for several reasons.
First, comparable pharmaceutical license agreements are identifiable. The pharmaceutical industry is characterized by a relatively robust market for technology licensing, in which companies routinely license patents, know-how, and regulatory filings to unrelated parties for commercialization in specific territories. This licensing activity generates a universe of comparable transactions from which arm's-length royalty rates can be derived. Whitmore Valuation Group has identified 14 such agreements that are sufficiently comparable to PPC's legacy IP license in terms of therapeutic area (oncology, immunology, or closely related fields), stage of development (approved or late-stage compounds), exclusivity (exclusive territorial licenses), geographic scope (comparable international territories), and functional profiles of the licensor and licensee.
Second, the comparability factors described in Treas. Reg. § 1.482-1(d) and § 1.482-4(c)(2) are sufficiently similar between PPC's legacy IP license and the identified CUT comparables. While no two pharmaceutical license agreements are identical, the differences between PPC's arrangement and the CUT comparables are of the type and magnitude that can be addressed through reliable comparability adjustments—adjustments to account for differences in contract terms, product maturity, geographic scope, and exclusivity.
Third, the CUT method provides a direct measure of the arm's-length royalty rate, without the need for the extensive modeling and projections required by alternative methods such as the income method or the profit split method. The CUT method is therefore less sensitive to data imperfections and subjective assumptions, making it the more reliable method under the circumstances.
The CUT analysis yields an interquartile range of 3.1% to 6.8%, with a median of 4.4%. PPC's 4.5% rate falls squarely within this range and is virtually at the median, providing strong support for the arm's-length nature of the legacy IP royalty rate.
2. CSA Cost-Sharing — Reasonably Anticipated Benefits Method
Under Treas. Reg. § 1.482-7(e), the share of intangible development activity costs borne by each participant in a qualified cost-sharing arrangement must be proportional to that participant's share of the reasonably anticipated benefits from the IDA. The RAB method is the prescribed regulatory method for determining cost-sharing ratios under a QCSA, and it is therefore the appropriate method for evaluating PPC's cost-sharing ratios.
PPC's RAB shares are calculated using prospective revenue projections for the Americas and non-Americas territories, which is one of several permitted bases for measuring RAB under the regulations. The revenue-based RAB approach is widely used in practice and has been accepted by the IRS and the Tax Court in prior cases. PPC's projections produced PBI RAB shares ranging from 38.2% in 2017 to 42.7% in 2020, reflecting the growth of PBI's non-Americas revenues relative to PPC's Americas revenues.
The IRS may challenge PPC's RAB projections on several grounds. First, the IRS may argue that PPC's ex ante revenue projections systematically understated non-Americas revenues, resulting in an RAB share that is too low and a corresponding underpayment of cost-sharing costs by PBI. Second, the IRS may argue that alternative RAB bases—such as operating profit rather than revenue—would produce higher PBI shares and would be more appropriate given the differences in profitability between the Americas and non-Americas territories. Third, the IRS may argue that the reasonableness of PPC's projections should be evaluated in light of actual outcomes, notwithstanding the general principle that RAB must be established prospectively based on reasonable expectations at the time the projections are made.
With respect to the IRS's burden on this issue, it is important to note that the IRS must demonstrate that PPC's RAB projections were unreasonable at the time they were made—not merely that they differed from actual results. The regulations contemplate that prospective RAB projections will not always match actual outcomes, and the occurrence of deviations between projected and actual revenues does not, by itself, establish that the projections were unreasonable. PPC should be prepared to support the reasonableness of its ex ante projections with contemporaneous business plans, board presentations, market analyses, and other documentation that was available at the time the projections were made.
3. PCT Valuation — Income Method/DCF
Under Treas. Reg. § 1.482-7(g), the PCT payment must reflect the arm's-length charge for the pre-existing intangible property contributed by a participant to the CSA. PPC used the income method, as described in Treas. Reg. § 1.482-7(g)(4), to value the pre-existing IP contributed to the CSA as of July 1, 2012. The income method is the most commonly used and most reliable method for PCT valuation where the intangible property at issue is unique and no comparable acquisition transactions exist from which a market-based valuation could be derived.
PPC's income method analysis employed a WACC of 9.8%, producing a PCT value of $312 million. Whitmore Valuation Group's independent analysis, using a range of reasonable assumptions for the discount rate and revenue projections, produces a range of $278 million to $361 million, within which PPC's $312 million payment falls.
The critical variable in the income method is the discount rate. PPC's WACC of 9.8% reflects pharmaceutical-industry risk premiums, including the beta of comparable pharmaceutical companies, the equity risk premium for the pharmaceutical sector, the size premium for companies of PPC's market capitalization, and the specific risk premium associated with the early-stage development uncertainty and regulatory risk inherent in PPC's intangible property portfolio at the time of the CSA's effective date.
The IRS may argue for a significantly lower discount rate—potentially as low as 7.2%, based on the preliminary indications from the examination team. The 260-basis-point difference between PPC's 9.8% WACC and the IRS's potential 7.2% WACC has a dramatic effect on the DCF output. All else being equal, a lower discount rate produces a higher present value of future income streams, which in turn produces a higher PCT valuation. Based on the IRS's internal analysis (as inferred from the examination team's preliminary IDR requests and the assignment of Dr. Washburne), the IRS may seek to inflate the PCT value to as high as $852 million—a figure that would represent a more than $540 million increase over PPC's $312 million payment and would generate a substantial § 482 adjustment.
The IRS may also challenge PPC's revenue projections, arguing that PPC underestimated the future revenue potential of the pre-existing intangibles at the time of the CSA's effective date. Additionally, the IRS may argue that PPC failed to include certain categories of intangible property in the PCT valuation—such as workforce in place, goodwill, customer relationships, and other residual intangibles—that should have been treated as pre-existing resources, capabilities, or rights contributed to the CSA.
PPC should direct Whitmore to prepare a rigorous WACC analysis using pharmaceutical-industry beta comparables, size premiums, and specific risk premium justifications. The analysis should also address the sensitivity of the DCF output to variations in the discount rate and revenue assumptions, demonstrating that PPC's $312 million payment is robust across a reasonable range of assumptions.
E. Burden of Proof Considera

PRIVILEGED & CONFIDENTIAL — ATTORNEY WORK PRODUCT

MEMORANDUM

MATTER NO.: 1018-00009

TAX YEARS AT ISSUE: 2017, 2018, 2019, 2020

IRS EXAM TEAM ID: LB&I-NE-TP-2022-00641

Record

Parties

Dates

Amounts